Company Overview and News

to your dashboard

Headline News

Sector Report: How The Pressure On Generic Drugs Is Creating Tailwind For Branded Molecules

2018-01-19 seekingalpha
"If you hope to have more money tomorrow than you have today, you've got to put a chunk of your assets into stocks. Sooner or later, a portfolio of stocks or stock mutual funds will turn out to be a lot more valuable than a portfolio of bonds or CDs or money-market funds." - Peter Lynch (124-0)

Marketplace Authors' Top Picks For 2018

2018-01-06 seekingalpha
We wrap up our Year End Marketplace Roundtable series with the good stuff - authors' sharing some of their best ideas for 2018. (1203-10)

Biotech Analysis Central Pharma News: Protalix Phase 2 Success, Achaogen NDA Acceptance, GW Pharmaceuticals FDA Advance

2018-01-03 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (113-5)

Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results

2018-01-03 seekingalpha
Today we will discuss the latest update from Achaogen (AKAO). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market. According to Blake Wise, Achaogen’s CEO, the number of confirmed cases of CRE annually in the U.S. alone total at least 70,000. More important, Wise noted is that the number is projected to double by 2022. (224-6)

BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106

2018-01-02 reuters

Wired News - Protalix BioTherapeutics Granted Orphan Drug Designation for the Treatment of Fabry Disease

2017-12-29 accesswire
LONDON, UK / ACCESSWIRE / December 29, 2017 / has just released a free research report on Protalix BioTherapeutics, Inc. (NYSE: PLX). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On December 27, 2017, the Company announced that the European Commission (EC) granted Orphan Drug Designation (ODD) for pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease. (59-0)

Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

2017-12-28 zacks
Protalix BioTherapeutics, Inc. (PLX - Free Report) announced that the European Commission (“EC”) has granted orphan drug designation to its pipeline candidate, PRX-102 (pegunigalsidase alfa). The small biotech company is developing PRX-102 for patients with Fabry disease, a rare inherited genetic lysosomal disorder. (78-1)

BRIEF-Protalix Biotherapeutics' PRX-102 Granted Orphan Drug Designation By The European Commission

2017-12-27 reuters

Protalix Biotherapeutics: An Update On The Fabry Disease Franchise

2017-11-23 seekingalpha
PRX-102 causes a lower level of antibody that, in and of itself, interestingly stayed in the body briefly. (59-9)

Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU

2017-11-15 accesswire
LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Protalix BioTherapeutics, Inc. (NYSE: PLX), following which we have published a free report that can be viewed by signing up at The Company announced on November 13, 2017, that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the Orphan Medicinal Product Application for PRX-102 (pegunigalsidase alfa) for the treatment of Fabry disease. (77-1)

An Integrated BioSci Research On Protalix - The Top BioSci Catalyst For 2018

2017-11-01 seekingalpha
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). (110-6)

Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%

2017-10-18 zacks
Protalix BioTherapeutics, Inc (PLX - Free Report) was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $0.56–$0.63 in the past one-month time frame, witnessed a sharp increase yesterday. (275-3)

Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q2 2017 Results - Earnings Call Transcript

2017-08-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Inc., Second Quarter 2017 Financial Results and Corporate Update Conference. At this time all participants are in a listen-only mode. Later we'll conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder this conference call is being recorded. (0-3)

Protalix Is Undervalued With Upcoming Catalysts

2017-07-20 seekingalpha
A flurry of recent positive developments have not translated into a substantial increase in the share price of Protalix. (0-7)

Daily Technical Summary Reports on Railroads Stocks -- Kansas City Southern, Norfolk Southern, Canadian National Railway, and Trinity Industries

2017-07-19 prnewswire
If you want a Stock Review on KSU, NSC, CNI, or TRN then come over to and sign up for your free customized report today. shifts focus on the Railroads industry, which is engaged in the operation of railroad tracks and/or trains. Railroad companies transport cargo or people, often over long distances. Lined up for review this morning are these four stocks: Kansas City Southern (NYSE: KSU), Norfolk Southern Corp.

Stock Research Report

Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system, or ProCellEx. The company developed its first commercial drug product, ElelysoTM, using its ProCellEx system and The company is now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With its experience to date, The company believe ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The company is now also applying the unique properties of its ProCellEx system for the oral delivery of therapeutic proteins.

On May 1, 2012, the F...

Click for full article
CUSIP: 74365A101